P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

Podobne zapisy

• P1151: BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
  od: Gloria Ines Iacoboni Garcia-Calvo, i wsp.
  Wydane: (2023-08-01)
• P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
  od: K. Rejeski, i wsp.
  Wydane: (2022-06-01)
• Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
  od: Frederick L. Locke, i wsp.
  Wydane: (2025-06-01)
• OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL
  od: Yuliya Linhares, i wsp.
  Wydane: (2024-12-01)
• Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study
  od: Alison Sehgal, i wsp.
  Wydane: (2025-08-01)